MEDFORD, Mass.--(BUSINESS WIRE)--Sunflower Therapeutics (Sunflower), a public benefit corporation transforming global access to protein manufacturing capacity for diverse applications, announced today the oversubscription of a $3M Simple Agreement for Future Equity (SAFE), which underscores ongoing support for the company’s commercial goals. This oversubscription provides the necessary runway to support the continued launch of Sunflower’s innovative Daisy Petal™ and Dahlia Petal™ perfusion ferm...
Read the full news release here
